Understanding the interactions between human immune cells and tumors is paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses. NSG™* and NSG™-SGM3* mice are a proven host for engraftment of human tumors or establishment of human immunity following hematopoietic stem cell transplantation. Here, we provide evidence that NSG and NSG-SGM3 mice engrafted with hematopoietic stem cells (collectively referred to here as “humanized NSG mice”) can support the growth of allogeneic human tumors. The human tumors respond to standard-of-care chemotherapeutics, targeted therapies, and to immune check-point inhibitors clinically proven to initiate cytotoxic activity towards the tumor. Tumor-bearing, humanized NSG mice (the Onco- Hu™* mouse offered exclusively from The Jackson Laboratory) are a new and valuable preclinical testing platform for immuno-oncology.
Clinical and Research Services, JAX Mice,, "Onco-Hu™ Models: Humanized NSG™ and NSG™-SGM3 Mice for Immuno-Oncology" (2016). Faculty Research 2016. 216.